基于PET/CT影像组学与临床因素联合模型及列线图预测肺腺癌EGFR突变的临床实用性研究
该回顾性研究纳入583例肺腺癌患者(EGFR突变295例,占50.60%;无突变288例,占49.40%),分别构建PET/CT、CT、PET影像组学模型及PET/CT影像组学-临床联合列线图模型预测EGFR突变。PET/CT影像组学模型AUC为0.76,优于PET模型(AUC=0.71,p=0.002),但与CT模型(AUC=0.74,p=0.098)差异未达统计学显著;联合模型AUC为0.84,优于PET/CT影像组学模型(p<0.001)和临床模型(AUC=0.81,p<0.001)。
要点
- PET/CT影像组学-临床联合列线图模型预测肺腺癌EGFR突变AUC达0.84,优于单纯影像组学模型和临床模型。
- PET/CT影像组学模型AUC为0.76,优于PET模型(AUC=0.71,p=0.002),与CT模型(AUC=0.74,p=0.098)差异未达统计学显著。
- 决策曲线分析用于评估该风险评分模型的临床净获益和临床实用性。
核心结论
- PET/CT影像组学-临床联合模型在预测肺腺癌EGFR突变方面具有优势。
- 肺肿瘤影像组学可提高PET/CT预测临床肺腺癌EGFR突变的效率。
- 研究开发了用于预测EGFR突变的影像组学列线图。
研究设计与样本
- 回顾性研究,纳入583例肺腺癌患者,其中EGFR突变295例(50.60%),无EGFR突变288例(49.40%)。
- 同期收集与肺腺癌相关的临床危险因素。
- 采用多因素逻辑回归分析分别构建PET/CT、CT和PET影像组学模型预测EGFR突变。
- 通过列线图分析构建PET/CT影像组学-临床联合模型。
- 采用受试者工作特征曲线分析检验诊断性能和临床净获益,采用决策曲线分析评估临床实用性。
诊断标准与关键数值
- PET/CT影像组学模型预测EGFR突变AUC=0.76,优于PET模型(AUC=0.71,Delong检验Z=3.03,p=0.002),与CT模型(AUC=0.74,Delong检验Z=1.66,p=0.098)差异未达统计学显著。
- PET/CT影像组学-临床联合模型预测EGFR突变AUC=0.84,优于PET/CT影像组学模型(AUC=0.76,Delong检验D=2.70,df=790.81,p<0.001)。
- PET/CT影像组学-临床联合模型预测EGFR突变AUC=0.84,优于临床模型(AUC=0.81,Delong检验Z=3.46,p<0.001)。
临床应用与阅片要点
- 基于PET/CT的影像组学特征可提高预测临床肺腺癌EGFR突变的效率。
- 影像组学列线图可用于预测肺腺癌EGFR突变。
- PET/CT影像组学-临床联合模型在预测肺腺癌EGFR突变方面具有优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aims to develop a clinically practical model to predict EGFR mutation in lung adenocarcinoma patients according to radiomics signatures based on PET/CT and clinical risk factors.
METHODS: This retrospective study included 583 lung adenocarcinoma patients, including 295 (50.60%) patients with EGFR mutation and 288 (49.40%) patients without EGFR mutation. The clinical risk factors associated with lung adenocarcinoma were collected at the same time. We developed PET/CT, CT, and PET radiomics models for the prediction of EGFR mutation using multivariate logistic regression analysis, respectively. We also constructed a combined PET/CT radiomics-clinical model by nomogram analysis. The diagnostic performance and clinical net benefit of this risk-scoring model were examined via receiver operating characteristic (ROC) curve analysis while the clinical usefulness of this model was evaluated by decision curve analysis (DCA).
RESULTS: The ROC analysis showed predictive performance for the PET/CT radiomics model (AUC = 0.76), better than the PET model (AUC = 0.71, Delong test: Z = 3.03, p value = 0.002) and the CT model (AUC = 0.74, Delong test: Z = 1.66, p value = 0.098). Also, the PET/CT radiomics-clinical combined model has a better performance (AUC = 0.84) to predict EGFR mutation than the PET/CT radiomics model (AUC = 0.76, Delong test: D = 2.70, df = 790.81, p value < 0.001) or the clinical model (AUC = 0.81, Delong test: Z = 3.46, p value < 0.001).
CONCLUSIONS: We demonstrated that the combined PET/CT radiomics-clinical model has an advantage to predict EGFR mutation in lung adenocarcinoma.
KEY POINTS: • Radiomics from lung tumor increase the efficiency of the prediction for EGFR mutation in clinical lung adenocarcinoma on PET/CT. • A radiomic nomogram was developed to predict EGFR mutation. • Combining PET/CT radiomics-clinical model has an advantage to predict EGFR mutation.
引用
- Chang C, Zhou S, Yu H, et al. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma. Eur Radiol. 2021. PMID: 33544167. doi:10.1007/s00330-020-07676-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。